Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Market Closed 05-17 16:00:00 EDT

23.12

+1.56

+7.24%

盘后23.15

+0.03+0.13%

19:59 EDT

High23.39	Low21.36	Vol774.47K
Open22.12	D1 Closing21.56	Amplitude9.42%
Mkt Cap1.11B	Tradable Cap1.04B	Total Shares47.98M
T/O17.58M	T/O Rate1.72%	Tradable Shares44.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":23.12,"timestamp":1715976000000,"preClose":21.56,"halted":0,"volume":774468,"hourTrading":{"tag":"盘后","latestPrice":23.15,"preClose":23.12,"latestTime":"19:59 EDT","volume":4454,"amount":102747.0905,"timestamp":1715990372810},"delay":0,"floatShares":44974600,"shares":47976166,"eps":-2.1719,"marketStatus":"Market Closed","change":1.56,"latestTime":"05-17 16:00:00 EDT","open":22.12,"high":23.39,"low":21.36,"amount":17581912.901964,"amplitude":0.094156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.1719,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":21.56,"preHourTrading":{"tag":"盘前","latestPrice":22.19,"preClose":21.56,"latestTime":"09:28 EDT","volume":3818,"amount":83665.83845,"timestamp":1715952533233},"postHourTrading":{"tag":"盘后","latestPrice":23.15,"preClose":23.12,"latestTime":"19:59 EDT","volume":4454,"amount":102747.0905,"timestamp":1715990372810},"volumeRatio":0.8583414376881283},"requestUrl":"/m/hq/s/SAVA/wiki","defaultTab":"wiki","newsList":[{"id":"2436915938","title":"Cassava Sciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2436915938","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2436915938?lang=en_us&edition=fundamental","pubTime":"2024-05-17 20:22","pubTimestamp":1715948520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SAVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 17, 2024 08:22 ET (12:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435549208","title":"Insider Stock Buying Reaches US$831.4k On Cassava Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2435549208","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2435549208?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:55","pubTimestamp":1715691340,"startTime":"0","endTime":"0","summary":"In the last year, multiple insiders have substantially increased their holdings of Cassava Sciences, Inc. ( NASDAQ:SAVA...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sava/cassava-sciences/news/insider-stock-buying-reaches-us8314k-on-cassava-sciences","is_publish_highlight":false,"gpt_icon":0},{"id":"2435307136","title":"Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified","url":"https://stock-news.laohu8.com/highlight/detail?id=2435307136","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435307136?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:25","pubTimestamp":1715631922,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from Jon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cassava-sciences-progresses-in-phase-3-trials-secures-strong-cash-position-a-buy-rating-justified?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cassava-sciences-progresses-in-phase-3-trials-secures-strong-cash-position-a-buy-rating-justified?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434897852","title":"Cassava Sciences Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2434897852","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434897852?lang=en_us&edition=fundamental","pubTime":"2024-05-11 05:50","pubTimestamp":1715377833,"startTime":"0","endTime":"0","summary":"* Cassava Sciences Inc    reported quarterly adjusted earnings of 58 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -58 cents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434897916","title":"Market Today: Xponential CEO Suspended Amid Fraud Allegations, EV Tariffs Loom","url":"https://stock-news.laohu8.com/highlight/detail?id=2434897916","media":"GuruFocus","top":-1,"share":"https://ttm.financial/m/news/2434897916?lang=en_us&edition=fundamental","pubTime":"2024-05-11 05:32","pubTimestamp":1715376744,"startTime":"0","endTime":"0","summary":"Today's trading session concluded with mixed results, despite the overall gains for the week. The S&P 500 edged up by 0.2% from yesterday, marking a 1.9% increase from the previous Friday. Conversely, the Nasdaq Composite experienced a slight decline from yesterday, although it still managed a weekly rise of 1.1%.Market dynamics shifted following the release of the preliminary University of Michigan Index of Consumer Sentiment for May, which fell to 67.4 against expectations of 76.5. This report also highlighted a rise in inflation expectations for the coming year, increasing to 3.5% from 3.2%.Reacting to the sentiment data, Treasury yields saw significant movement. The 10-year note yield rose by six basis points to settle at 4.50%, while the 2-year note yield also increased by six basis points, closing the week at 4.87%.Major tech stocks like Apple  initially saw gains but later reversed, with AAPL closing at $183.05, down by 0.8% despite peaking at a 0.3% increase earlier in the day.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2435165/market-today-xponential-ceo-suspended-amid-fraud-allegations-ev-tariffs-loom","is_publish_highlight":false,"gpt_icon":0},{"id":"2434189179","title":"Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2434189179","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434189179?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:48","pubTimestamp":1715374103,"startTime":"0","endTime":"0","summary":"Cassava Sciences swung to Q1 2024 net income -- representing a beat -- while reporting that more than 735 patients have completed either of the drugmaker's two phase 3 trials for Alzheimer's disease candidate simufilam. In the quarter, net income was $25M compared to a net loss of $24.3 million in the year-ago period. EPS, basic, was $0.58 compared to -$0.58 in Q1 2023. Cassava attributed the income to a change in fair value of warrant liabilities. However, the company noted that this gain was partially offset by increases in patient enrollment and costs to conduct the phase 3 simufilam program. The company was also helped by a ~25% year-over-year decrease in overall operating expenses to $19.9M. The biopharma noted that the R&D spending decline was the result of finishing patient screening and enrollment for the phase 3 simufilam program in fall 2023. Regarding simufilam development, Cassava  said that ~800 patients have been randomized in the 52-week RETHINK-ALZ study, while ~1,100 p","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975486538/image_1975486538.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975486538/image_1975486538.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104856-cassava-swings-q1-profit-more-patients-finish-simufilam-phase-3-trials","is_publish_highlight":false,"gpt_icon":0},{"id":"2434896261","title":"Cassava Sciences GAAP EPS of -$0.43 beats by $0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2434896261","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434896261?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:07","pubTimestamp":1715371647,"startTime":"0","endTime":"0","summary":"Cassava Sciences press release : Q1 GAAP EPS of -$0.43  beats by $0.03. At March 31, 2024, cash and cash equivalents were $124.2 million, with no debt. The total gross proceeds received from the cash-exercise of Warrants were $126.3 million, including approximately $104.0 million received in April and May 2024.  Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.. Shares +1.53%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104820-cassava-sciences-gaap-eps-of-0_43-beats-0_03","is_publish_highlight":false,"gpt_icon":0},{"id":"2434969128","title":"BRIEF-Cassava Sciences Q1 Basic EPS USD 0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2434969128","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434969128?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:02","pubTimestamp":1715371365,"startTime":"0","endTime":"0","summary":"May 10 (Reuters) - Cassava Sciences Q1 operating income USD -19.934 million. * Q1 net income USD 25.043 million * Q1 operating expenses USD 19.934 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434966828","title":"Cassava Sciences Q1 EPS $(0.43) Beats $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434966828","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434966828?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:02","pubTimestamp":1715371360,"startTime":"0","endTime":"0","summary":"Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 25.86 percent increase over losses of $(0.58) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38769867/cassava-sciences-q1-eps-0-43-beats-0-46-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434896065","title":"Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2434896065","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2434896065?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:02","pubTimestamp":1715371320,"startTime":"0","endTime":"0","summary":"$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.AUSTIN, Texas, May 10, 2024  -- Cassava Sciences, Inc. , a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.Data Safety and Monitoring Board  – The DSMB is composed of independent clinical research experts who periodically review interim patient safety data. Routi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-reports-q1-2024-200200473.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434862922","title":"Cassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?","url":"https://stock-news.laohu8.com/highlight/detail?id=2434862922","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434862922?lang=en_us&edition=fundamental","pubTime":"2024-05-11 01:09","pubTimestamp":1715360964,"startTime":"0","endTime":"0","summary":"According to the Alzheimer’s Association, approximately 1 in 9 individuals aged 65 and older in the United States (7 million Americans) are diagnos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cassava-sciences-nasdaqsava-cracking-alzheimers-or-succumbing-to-short-sellers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cassava-sciences-nasdaqsava-cracking-alzheimers-or-succumbing-to-short-sellers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434737860","title":"Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box","url":"https://stock-news.laohu8.com/highlight/detail?id=2434737860","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434737860?lang=en_us&edition=fundamental","pubTime":"2024-05-10 08:43","pubTimestamp":1715301802,"startTime":"0","endTime":"0","summary":"Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.Many current drug candidates for Alzheimer's ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/97940600/image_97940600.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/97940600/image_97940600.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4691607-annovis-anavex-cassava-sciences-investment-avxl-probably-still-warranted","is_publish_highlight":false,"gpt_icon":0},{"id":"2433720227","title":"Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2433720227","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433720227?lang=en_us&edition=fundamental","pubTime":"2024-05-08 23:00","pubTimestamp":1715180400,"startTime":"0","endTime":"0","summary":"Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share. B. Dyson Capital Advisors served as exclusive financial advisor on the Warrant distribution.“We are grateful to so many shareholders who continue to show support for Cassava Sciences and its mission to develop a novel drug candidate for Alzheimer’s disease,” said Remi Barbier, President and CEO. “Given the outcome of our first Warrant distribution, it could be interesting to do it again at some point in the future.”Warrant holders had the option to cash-exercise their Warrants or to sell their Warrants on the open market. Warrant holders who opted to exercise their Warrants paid cash to the Company under the terms and conditions of a warrant agreement previously filed with the U.S. Securities and Exchange Commission .This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-sciences-announces-over-125-150000120.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432574856","title":"Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2432574856","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432574856?lang=en_us&edition=fundamental","pubTime":"2024-05-01 13:10","pubTimestamp":1714540200,"startTime":"0","endTime":"0","summary":"End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of Guara","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/01/2873328/8339/en/Tomorrow-is-Last-Day-to-Trade-SAVAW-Warrants-on-NASDAQ.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432858128","title":"Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432858128","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432858128?lang=en_us&edition=fundamental","pubTime":"2024-05-01 04:00","pubTimestamp":1714507200,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc. stock price fell sharply in October last year, as the lead drug pitolisant - approved to treat narcolepsy - missed endpoints in a late stage IH study.The company's Q","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368010116/image_1368010116.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368010116/image_1368010116.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687692-harmony-biosciences-companys-q1-update-music-to-investor-ears-upgrade","is_publish_highlight":false,"gpt_icon":0},{"id":"2430273553","title":"Cassava Sciences Inc    expected to post a loss of 46 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2430273553","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2430273553?lang=en_us&edition=fundamental","pubTime":"2024-04-26 19:52","pubTimestamp":1714132329,"startTime":"0","endTime":"0","summary":"* Cassava Sciences Inc     is expected to show no change in quarterly revenue when it reports  results on April 29 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427807005","title":"Redemption Date Announced for Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2427807005","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2427807005?lang=en_us&edition=fundamental","pubTime":"2024-04-15 21:20","pubTimestamp":1713187200,"startTime":"0","endTime":"0","summary":"Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value.AUSTIN, Texas, April 15, 2024  -- Cassava Sciences, Inc.   today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 . Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an effective price of approximately $22.00 per share.Any Warrants that are not validly exercised by 5:00 p.m. New York City time on May 6, 2024 will be redeemed by the Company on May 7, 2024  for a nominal payment of $0.001 per warrant . The Redemption Price will become due and payable with respect to each outstanding warrant on the Redemption Date. Warrants shall terminate and expire upon payment of the Redemption Price on the Redemption Date.Details of the Warrant Distribution and Bonus Share Program. For any further details re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redemption-date-announced-warrants-132000877.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425657604","title":"Who is using oxycodone in NSW and why?","url":"https://stock-news.laohu8.com/highlight/detail?id=2425657604","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2425657604?lang=en_us&edition=fundamental","pubTime":"2024-04-08 08:32","pubTimestamp":1712536320,"startTime":"0","endTime":"0","summary":"Linked health data study sheds light on oxycodone use in NSW. Hospital stay or ED visit and therapeutic procedures common reasons for oxycodone initiation. Likelihood of prescription of oxycodone increased with age and was elevated for women of childbearing age and people living in regional areas. Oxycodone  is a strong opioid medicine that is commonly prescribed around the world to manage cancer as well as acute and chronic pain.In recent decades, its use has been subject to much scrutiny due to a prescription opioid addiction epidemic in America. Despite this attention, little is known about why, and in which settings, opioids are prescribed in Australia.Harmful use of prescription opioids can result in addiction, overdose and even death. To understand the associations between opioid use and sociodemographic factors, researchers from the Medicines Intelligence Research Program and National Drug and Alcohol Research Centre  at UNSW Sydney looked at linked data involving more than 800,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23036747","is_publish_highlight":false,"gpt_icon":0},{"id":"2425817530","title":"CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2425817530","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2425817530?lang=en_us&edition=fundamental","pubTime":"2024-04-05 18:00","pubTimestamp":1712311200,"startTime":"0","endTime":"0","summary":"NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23031880","is_publish_highlight":false,"gpt_icon":0},{"id":"2423437838","title":"Citigroup Inc. Sells 9513 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2423437838","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2423437838?lang=en_us&edition=fundamental","pubTime":"2024-03-29 16:49","pubTimestamp":1711702177,"startTime":"0","endTime":"0","summary":"Citigroup Inc. Sells 9513 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMib2h0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yOS9jaXRpZ3JvdXAtaW5jLXNlbGxzLTk1MTMtc2hhcmVzLW9mLWNhc3NhdmEtc2NpZW5jZXMtaW5jLW5hc2RhcXNhdmEuaHRtbNIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMib2h0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yOS9jaXRpZ3JvdXAtaW5jLXNlbGxzLTk1MTMtc2hhcmVzLW9mLWNhc3NhdmEtc2NpZW5jZXMtaW5jLW5hc2RhcXNhdmEuaHRtbNIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":0.1429},{"period":"1month","weight":0.087},{"period":"3month","weight":-0.0265},{"period":"6month","weight":0.0276},{"period":"1year","weight":-0.0613},{"period":"ytd","weight":0.0271}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.541667,"avgChangeRate":0.155421},{"month":2,"riseRate":0.416667,"avgChangeRate":0.028198},{"month":3,"riseRate":0.458333,"avgChangeRate":0.024377},{"month":4,"riseRate":0.583333,"avgChangeRate":0.060573},{"month":5,"riseRate":0.458333,"avgChangeRate":0.030139},{"month":6,"riseRate":0.478261,"avgChangeRate":0.002052},{"month":7,"riseRate":0.434783,"avgChangeRate":-0.033946},{"month":8,"riseRate":0.458333,"avgChangeRate":0.001895},{"month":9,"riseRate":0.583333,"avgChangeRate":0.111686},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.042533},{"month":11,"riseRate":0.625,"avgChangeRate":0.025539},{"month":12,"riseRate":0.375,"avgChangeRate":0.049835}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}